Synergy Pharmaceuticals (NASDAQ:SGYP) is scheduled to be announcing its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter.
Synergy Pharmaceuticals (NASDAQ:SGYP) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. The business had revenue of $12.25 million during the quarter, compared to analyst estimates of $10.20 million. On average, analysts expect Synergy Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ SGYP opened at $0.46 on Tuesday. Synergy Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $3.19. The firm has a market capitalization of $111.60 million, a P/E ratio of -0.45 and a beta of 2.38.
A number of equities analysts have issued reports on the stock. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Synergy Pharmaceuticals in a report on Tuesday, August 7th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Zacks Investment Research cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, BidaskClub cut Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $8.17.
COPYRIGHT VIOLATION WARNING: “Synergy Pharmaceuticals (SGYP) Set to Announce Quarterly Earnings on Thursday” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/06/synergy-pharmaceuticals-sgyp-set-to-announce-quarterly-earnings-on-thursday.html.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Featured Article: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.